Georg Schett, Fabian Müller, Jule Taubmann, Andreas Mackensen, Wei Wang, Rich A Furie, Ralf Gold, Aiden Haghikia, Peter A Merkel, Roberto Caricchio, Maria-Antonietta D'Agostino, Franco Locatelli, Carl H June, Dimitrios Mougiakakos
Chimeric antigen receptor (CAR) T cells are highly effective at targeting and eliminating cells of the B cell lineage. CAR T cell therapy has become a standard-of-care treatment for patients with relapsed or refractory B cell malignancies. In addition, the administration of genetically modified T cells with the capacity to deplete B cells and/or plasma cells has tremendous therapeutic potential in autoimmune diseases. In the past few years, CD19-based and B cell maturation antigen (BCMA)-based CAR T cell therapies have been applied to various B cell-mediated autoimmune diseases including systemic lupus erythematosus, idiopathic inflammatory myopathy, systemic sclerosis, neuromyelitis optica spectrum disorder, myasthenia gravis and multiple sclerosis...
September 2024: Nature Reviews. Rheumatology